<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214083</url>
  </required_header>
  <id_info>
    <org_study_id>CDA-2-014-09F</org_study_id>
    <nct_id>NCT01214083</nct_id>
  </id_info>
  <brief_title>N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence</brief_title>
  <official_title>N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether: (1) the combination of N-acetylcysteine +
      high-dose naltrexone (150 mg) works better than high-dose naltrexone (150 mg) alone in
      reducing alcohol drinking; and (2) high-dose naltrexone (150 mg) alone works better than
      low-dose naltrexone (50 mg) alone in reducing alcohol drinking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 3 groups (N-acetylcysteine plus naltrexone 150 mg, naltrexone 150 mg, and naltrexone 50
      mg) will be compared in a 12-week randomized, double-blind clinical trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2010</start_date>
  <completion_date type="Actual">October 30, 2016</completion_date>
  <primary_completion_date type="Actual">September 30, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Heavy Drinking Days</measure>
    <time_frame>week 1 and week 13</time_frame>
    <description>&quot;Percentage of heavy drinking days&quot; was measured by the Time Line Follow Back (TLFB) Method. ('Heavy drinking' was defined as 5 or more standard drinks per day for men and 4 or more standard drinks for women.) The percentage has a total range of 0%-100%. Higher percentages represent a worse outcome (i.e., more heavy drinking).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver Function Tests (AST)</measure>
    <time_frame>week 0 and week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penn Alcohol Craving Scale (PACS)</measure>
    <time_frame>week 1 and week 13</time_frame>
    <description>The Penn Alcohol Craving Scale is designed to assess alcohol craving severity. The scale has a total score range of 0-30. Higher values represent a worse outcome (i.e., higher craving).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obsessive Compulsive Drinking Scale (OCDS)</measure>
    <time_frame>week 1 and week 13</time_frame>
    <description>The Obsessive Compulsive Drinking Scale is designed to assess obsessive and compulsive aspects of alcoholism. The scale has a total score range of 0-56. Higher values represent a worse outcome (i.e., more alcohol problems).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>week 1 and week 13</time_frame>
    <description>The Clinical Global Impression is designed to assess overall severity of illness. The scale has a total score range of 1-7. Higher values represent a worse outcome (i.e., severe illness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</measure>
    <time_frame>week 1 and week 13</time_frame>
    <description>The Quality of Life Enjoyment and Satisfaction Questionnaire is designed to assess a quality of life. The scale has a total score range of 16-80. Higher values represent a better outcome (i.e., better quality of life).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Drinking Days</measure>
    <time_frame>week 1 and week 13</time_frame>
    <description>&quot;Percentage of drinking days&quot; was measured by the Time Line Follow Back (TLFB) Method. The percentage has a total range of 0%-100%. Higher percentages represent a worse outcome (i.e., more drinking days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drinks Per Drinking Days</measure>
    <time_frame>week 1 and week 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Function Tests (ALT)</measure>
    <time_frame>week 0 and week 13</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine + high-dose naltrexone (150 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose naltrexone (150 mg) alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose naltrexone (50 mg) alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine + high-dose naltrexone (150 mg)</intervention_name>
    <description>All subjects will be evaluated weekly for 12 weeks.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose naltrexone (150 mg) alone</intervention_name>
    <description>All subjects will be evaluated weekly for 12 weeks.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose naltrexone (50 mg) alone</intervention_name>
    <description>All subjects will be evaluated weekly for 12 weeks.</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-65 years

          -  alcohol dependence by DSM-IV criteria

          -  heavy drinking at least 6 times within the past month ('heavy drinking' defined as 5
             or more standard drinks per day for men and 4 or more standard drinks for women)

          -  able to provide informed consent

          -  a score of 6 or more on the Penn Alcohol Craving Scale (PACS)

          -  subject agrees not to take over-the-counter analgesics during the study

        Exclusion Criteria:

          -  current drug abuse or dependence by DSM-IV criteria (except nicotine and marijuana)

          -  current psychotic disorders or bipolar disorders

          -  current suicidal or homicidal ideation

          -  positive illicit drug screen test (except marijuana)

          -  ongoing narcotic use or risks for narcotic use during the study

          -  increased risk for severe alcohol withdrawal by a score of 10 or more on the Clinical
             Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar)

          -  clinically significant cardiac, hepatic, renal, neurologic, or pulmonary disease

          -  baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater
             than 3 times normal

          -  current use of disulfiram, acamprosate or topiramate

          -  pregnant or nursing, or inadequate birth control methods in women of childbearing
             potential

          -  alcohol breathalyzer level 0.08 or more at the screening visit

          -  severe alcohol withdrawal (delirium tremens or withdrawal seizures) within the past
             year

          -  currently requiring inpatient treatment for treating alcohol dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gihyun Yoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System West Haven Campus, West Haven, CT</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2010</study_first_submitted>
  <study_first_submitted_qc>September 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2010</study_first_posted>
  <results_first_submitted>December 12, 2016</results_first_submitted>
  <results_first_submitted_qc>February 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 28, 2017</results_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N-acetylcysteine</keyword>
  <keyword>naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 111 subjects signed consent. Of 111 subjects, 95 subjects were qualified for the trial.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
          <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>High-dose Naltrexone (150 mg) Alone</title>
          <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Low-dose Naltrexone (50 mg) Alone</title>
          <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
          <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>High-dose Naltrexone (150 mg) Alone</title>
          <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Low-dose Naltrexone (50 mg) Alone</title>
          <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="31"/>
            <count group_id="B4" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Heavy Drinking Days</title>
        <description>&quot;Percentage of heavy drinking days&quot; was measured by the Time Line Follow Back (TLFB) Method. ('Heavy drinking' was defined as 5 or more standard drinks per day for men and 4 or more standard drinks for women.) The percentage has a total range of 0%-100%. Higher percentages represent a worse outcome (i.e., more heavy drinking).</description>
        <time_frame>week 1 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Heavy Drinking Days</title>
          <description>&quot;Percentage of heavy drinking days&quot; was measured by the Time Line Follow Back (TLFB) Method. ('Heavy drinking' was defined as 5 or more standard drinks per day for men and 4 or more standard drinks for women.) The percentage has a total range of 0%-100%. Higher percentages represent a worse outcome (i.e., more heavy drinking).</description>
          <units>percentage of heavy drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of heavy drinking days at week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="4.5"/>
                    <measurement group_id="O2" value="50.6" spread="4.3"/>
                    <measurement group_id="O3" value="44.0" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of heavy drinking days at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="5.6"/>
                    <measurement group_id="O2" value="3.4" spread="5.1"/>
                    <measurement group_id="O3" value="3.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Function Tests (AST)</title>
        <time_frame>week 0 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function Tests (AST)</title>
          <units>units/liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liver function tests (AST) at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.7" spread="6.6"/>
                    <measurement group_id="O2" value="29.0" spread="6.4"/>
                    <measurement group_id="O3" value="30.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver function tests (AST) at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" spread="7.9"/>
                    <measurement group_id="O2" value="32.1" spread="7.4"/>
                    <measurement group_id="O3" value="22.2" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penn Alcohol Craving Scale (PACS)</title>
        <description>The Penn Alcohol Craving Scale is designed to assess alcohol craving severity. The scale has a total score range of 0-30. Higher values represent a worse outcome (i.e., higher craving).</description>
        <time_frame>week 1 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Penn Alcohol Craving Scale (PACS)</title>
          <description>The Penn Alcohol Craving Scale is designed to assess alcohol craving severity. The scale has a total score range of 0-30. Higher values represent a worse outcome (i.e., higher craving).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Penn Alcohol Craving Scale at week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="1.1"/>
                    <measurement group_id="O2" value="18.4" spread="1.1"/>
                    <measurement group_id="O3" value="16.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Penn Alcohol Craving Scale at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.4"/>
                    <measurement group_id="O2" value="8.3" spread="1.3"/>
                    <measurement group_id="O3" value="6.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Obsessive Compulsive Drinking Scale (OCDS)</title>
        <description>The Obsessive Compulsive Drinking Scale is designed to assess obsessive and compulsive aspects of alcoholism. The scale has a total score range of 0-56. Higher values represent a worse outcome (i.e., more alcohol problems).</description>
        <time_frame>week 1 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Obsessive Compulsive Drinking Scale (OCDS)</title>
          <description>The Obsessive Compulsive Drinking Scale is designed to assess obsessive and compulsive aspects of alcoholism. The scale has a total score range of 0-56. Higher values represent a worse outcome (i.e., more alcohol problems).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Obsessive Compulsive Drinking Scale at week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="1.8"/>
                    <measurement group_id="O2" value="29.0" spread="1.7"/>
                    <measurement group_id="O3" value="24.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obsessive Compulsive Drinking Scale at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.1"/>
                    <measurement group_id="O2" value="14.0" spread="1.9"/>
                    <measurement group_id="O3" value="9.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression (CGI)</title>
        <description>The Clinical Global Impression is designed to assess overall severity of illness. The scale has a total score range of 1-7. Higher values represent a worse outcome (i.e., severe illness).</description>
        <time_frame>week 1 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression (CGI)</title>
          <description>The Clinical Global Impression is designed to assess overall severity of illness. The scale has a total score range of 1-7. Higher values represent a worse outcome (i.e., severe illness).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Clinical Global Impression at week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="0.1"/>
                    <measurement group_id="O2" value="3.7" spread="0.1"/>
                    <measurement group_id="O3" value="3.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Global Impression at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="0.2"/>
                    <measurement group_id="O2" value="1.7" spread="0.2"/>
                    <measurement group_id="O3" value="1.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</title>
        <description>The Quality of Life Enjoyment and Satisfaction Questionnaire is designed to assess a quality of life. The scale has a total score range of 16-80. Higher values represent a better outcome (i.e., better quality of life).</description>
        <time_frame>week 1 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)</title>
          <description>The Quality of Life Enjoyment and Satisfaction Questionnaire is designed to assess a quality of life. The scale has a total score range of 16-80. Higher values represent a better outcome (i.e., better quality of life).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Q-LES-Q at week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="1.9"/>
                    <measurement group_id="O2" value="53.8" spread="1.8"/>
                    <measurement group_id="O3" value="55.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Q-LES-Q at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6" spread="2.1"/>
                    <measurement group_id="O2" value="59.6" spread="2.0"/>
                    <measurement group_id="O3" value="63.9" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Drinking Days</title>
        <description>&quot;Percentage of drinking days&quot; was measured by the Time Line Follow Back (TLFB) Method. The percentage has a total range of 0%-100%. Higher percentages represent a worse outcome (i.e., more drinking days).</description>
        <time_frame>week 1 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Drinking Days</title>
          <description>&quot;Percentage of drinking days&quot; was measured by the Time Line Follow Back (TLFB) Method. The percentage has a total range of 0%-100%. Higher percentages represent a worse outcome (i.e., more drinking days).</description>
          <units>percentage of drinking days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>percentage of drinking days at week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" spread="6.3"/>
                    <measurement group_id="O2" value="63.8" spread="6.1"/>
                    <measurement group_id="O3" value="55.3" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>percentage of drinking days at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="7.6"/>
                    <measurement group_id="O2" value="24.5" spread="7.0"/>
                    <measurement group_id="O3" value="18.2" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drinks Per Drinking Days</title>
        <time_frame>week 1 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Drinks Per Drinking Days</title>
          <units>drinks/drinking day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>drinks per drinking days at week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="0.6"/>
                    <measurement group_id="O2" value="5.9" spread="0.6"/>
                    <measurement group_id="O3" value="7.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>drinks per drinking days at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.6"/>
                    <measurement group_id="O2" value="1.2" spread="0.6"/>
                    <measurement group_id="O3" value="1.0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Liver Function Tests (ALT)</title>
        <time_frame>week 0 and week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
            <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Naltrexone (150 mg) Alone</title>
            <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Low-dose Naltrexone (50 mg) Alone</title>
            <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Liver Function Tests (ALT)</title>
          <units>units/liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Liver Function Tests (ALT) at week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4" spread="12.0"/>
                    <measurement group_id="O2" value="36.5" spread="11.6"/>
                    <measurement group_id="O3" value="34.7" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver Function Tests (ALT) at week 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6" spread="13.9"/>
                    <measurement group_id="O2" value="40.1" spread="13.0"/>
                    <measurement group_id="O3" value="31.3" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>N-acetylcysteine + High-dose Naltrexone (150 mg)</title>
          <description>N-acetylcysteine + high-dose naltrexone (150 mg): All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>High-dose Naltrexone (150 mg) Alone</title>
          <description>High-dose naltrexone (150 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Low-dose Naltrexone (50 mg) Alone</title>
          <description>Low-dose naltrexone (50 mg) alone: All subjects will be evaluated weekly for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gihyun Yoon, MD</name_or_title>
      <organization>VA Connecticut Healthcare System</organization>
      <phone>203-932-5711 ext 7421</phone>
      <email>gihyun.yoon@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

